Bruker Introduces iNTApharma(TM), a Label?Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC
MWN-AI** Summary
Bruker Corporation has launched an innovative platform called iNTApharma™, designed for the label-free characterization of nanoscale bioparticles, significantly advancing the fields of mRNA drug and gene therapy development. Introduced at SLAS 2026 in Boston, this cutting-edge system provides rapid, single-particle sensitivity measurements of size and concentration, all achievable in native aqueous media. The technology addresses the critical need for direct assessments of bio-nanoparticle populations without the modifications that labeling entails.
The iNTApharma system is particularly geared towards the growing demand in biopharmaceuticals, where the characterization of viral vectors, lipid nanoparticles (LNPs), and other nanoscale entities has become crucial for quality control processes. Its applications span various critical research areas, including extracellular vesicle (EV) analysis, adenovirus development, lentiviral vector studies, and formulation processes for nucleic acid delivery.
This platform is optimized for analyzing bioparticles ranging from 50 to 300 nanometers, allowing researchers to examine heterogeneous samples and resolve subpopulations within mixtures efficiently. The integration of well-plate reader functionality supports seamless, automated data acquisition that fits standard laboratory protocols without necessitating specialized sample preparation.
The advancements in iNTApharma stem from extensively developed optical measurement techniques at the Max-Planck Institute for the Science of Light, highlighting Bruker's commitment to ultramodern, accessible scientific tools. Early access systems are set to roll out in mid-2026, with plans for broader availability later that year, providing researchers and developers with vital capabilities for enhanced understanding and development in the rapidly expanding bio-nanoparticle landscape. This initiative underscores Bruker's leadership in post-genomic science, further pushing the envelope in innovative research and therapeutic solutions.
MWN-AI** Analysis
The introduction of Bruker Corporation's iNTApharma, a novel label-free platform for nanoparticle characterization, marks a significant advancement in the biopharmaceutical landscape. This system allows for rapid, native-state size and concentration measurements with single-particle sensitivity, particularly beneficial for mRNA drug development and gene therapy, segments poised for explosive growth.
As the market for mRNA therapeutics expands, driven by innovations in cell and gene therapies, the demand for high-precision, native-state characterization tools is set to increase. Bruker’s iNTApharma directly caters to this necessity, enabling accurate assessments without the need for complex sample preparation, making it an attractive investment for biopharma companies focused on quality control (QC) processes.
Given that the biopharmaceutical sector is experiencing double-digit growth rates, the timing for this launch is strategic. Companies that adopt the iNTApharma platform early can gain a competitive edge, ensuring their therapies meet the increasingly stringent QC requirements. The technology's ability to analyze heterogeneous samples and resolve subpopulations makes it particularly appealing for researchers working with lipid nanoparticles and viral vectors, which are critical in developing effective treatments.
From an investor's perspective, Bruker stands at an advantageous position. The company has consistently demonstrated leadership in developing high-performance scientific instruments and solutions essential for post-genomic research—an area that is expanding rapidly. As mRNA and gene therapies gain traction, Bruker's iNTApharma is likely to see increased adoption, bolstering revenue growth.
In summary, investing in Bruker (NASDAQ: BRKR) may prove beneficial as the company continues to innovate and capitalize on the burgeoning demand for advanced nanoparticle characterization technologies, aligning with market growth trends in biopharma and translational research.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
New iNTApharma system enables rapid, native?state size and concentration measurements with single?particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows
Bruker Corporation today announced the launch of iNTApharma , a label?free characterization platform that provides single?particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston , iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native?state assessment of bio-nanoparticle populations without labeling or chemical modifications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209780837/en/
Bruker’s iNTApharma system offers label-free, native characterization of vectors used in gene and cell therapy, and of LNPs used in mRNA drug delivery
Quantitative characterization of bioparticles under native buffer conditions is increasingly important in areas such as extracellular vesicle (EV) research , adenovirus (AdV and AAV) development , lentiviral vector analysis , and lipid nanoparticle (LNP) formulation for nucleic?acid delivery. Native?state nanoparticle tracking analysis (NTA) is becoming a requirement in biopharma quality control (QC) , where reliable assessment of particle size distributions, concentration levels, and subpopulations is essential for process consistency. As mRNA drug development, as well as cell and gene therapy development expand at double?digit growth rates, demand is increasing for high?precision, native?state characterization of viral vectors, LNPs, and other nanoscale bioparticles. iNTApharma addresses these needs through native-state, unlabeled measurements that support analysis across diverse biological matrices.
Optimized for bioparticles from 50 to 300 nanometers , iNTApharma provides measurement conditions well?suited for lipid nanoparticles, lentiviral vectors, adenoviruses, and extracellular vesicles. The system enables analysis of heterogeneous samples, including the resolution of subpopulations within mixtures. Its built?in well?plate reader functionality supports unattended and automated acquisition of datasets in standard laboratory workflows, without specialized sample preparation steps.
iNTApharma builds on optical measurement approaches developed at the Max-Planck-Institute for the Science of Light (MPL) in Erlangen, Germany, which are also used in mass photometry (MP). The platform translates advanced interferometric scattering (iSCAT) detection methods into accessible instrumentation for research, therapy development and QC environments.
“The technology is based on iSCAT microscopy, which has been used in a wide range of quantitative label?free investigations with single?molecule sensitivity,” said Prof. Vahid Sandoghdar , Director at the MPL, Germany. “ iNTApharma makes these capabilities broadly available and provides researchers with a tool that can deepen our understanding of nanoscale bioparticles.”
“Native?state, quantitative analysis of lipid nanoparticles, lentiviral vectors, and vesicle?scale bioparticles is a growing need across biopharma and translational research,” said Jürgen Srega, the President of the Bruker CALID Group . “With iNTApharma , we are introducing a fundamentally new tool that enables precise nanoparticle and bioparticle characterization for mRNA delivery, EV biology, gene therapy development, and nanoscale formulation science.”
Initial systems will be placed with early?access partners in the first half of 2026 to validate workflows under real?world conditions. Broader commercial availability is planned for H2 of 2026.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with customers, Bruker is enabling innovation and customer success in post-genomic life science molecular and cell biology, in disease biology and translational research, in specialty diagnostics, in applied and biopharma applications, as well as in industrial and cleantech research and QC, and in next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology, molecular diagnostics and therapeutic drug monitoring. For more information, please visit www.bruker.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260209780837/en/
Media Contact:
Natalie Spahl
Head of Global Marketing Bruker Optics
T: +49 173 96 624 25
E: natalie.spahl@bruker.com
Investor Contact:
Joe Kostka
Director, Investor Relations, Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
FAQ**
How does the launch of iNTApharma by Bruker Corporation (BRKR) position the company in the rapidly growing field of biopharmaceuticals and what are the anticipated impacts on their market share?
What are the expected advantages of the iNTApharma system in terms of accuracy and efficiency compared to existing technologies, and how might this influence Bruker Corporation (BRKR) stock performance?
Can you elaborate on how iNTApharma's capabilities will specifically enhance workflows in gene therapy and mRNA drug development, and how this aligns with Bruker Corporation's (BRKR) long-term strategic goals?
What measures will Bruker Corporation (BRKR) take to ensure the successful adoption of iNTApharma among early-access partners, and how will early feedback be used to refine the product before broader commercial availability?
**MWN-AI FAQ is based on asking OpenAI questions about Bruker Corporation (NASDAQ: BRKR).
NASDAQ: BRKR
BRKR Trading
-4.2% G/L:
$33.77 Last:
1,757,075 Volume:
$35.44 Open:
